Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metoprolol/tesofensine - Saniona

Drug Profile

Metoprolol/tesofensine - Saniona

Alternative Names: Tesofensine/metoprolol; Tesomet

Latest Information Update: 27 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Saniona
  • Class Antihyperglycaemics; Chlorobenzenes; Heterocyclic bicyclo compounds; Obesity therapies; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Biogenic monoamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome; Obesity
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Obesity; Prader-Willi syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 26 Jul 2021 Metoprolol/tesofensine - Saniona receives Orphan Drug status for Obesity in USA
  • 26 May 2021 Saniona plans a phase IIb trial for Hypothalamic obesity in USA in the second half of 2021
  • 26 May 2021 Saniona plans a phase IIb trial for Prader-Willi syndrome in USA in the second half of 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top